Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. has 1 pending office action currently under review. This action is handled by 1 distinct examiner, BARRON, SEAN C, who is the busiest examiner for the company with 1 busiest examiner pending action. The data shows 0 distinct art units associated with this activity, which is a notable administrative state for a pending matter.
Because there is only 1 pending office action, the company's current prosecution experience is defined by the interaction with BARRON, SEAN C. The lack of multiple examiners or art units suggests a very narrow or early-stage presence at the patent office. The success of the company's current patenting efforts depends entirely on the resolution of the 1 busiest examiner pending action under this single examiner's review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294715 | Application of GLUN2A and NMDA Receptor Containing GLUN2A as Targets in Screening Drugs for Treating Depression | BARRON, SEAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294715 | Application of GLUN2A and NMDA Receptor Containing GLUN2A as Targets in Screening Drugs for Treating Depression | BARRON, SEAN C | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294715 | Application of GLUN2A and NMDA Receptor Containing GLUN2A as Targets in Screening Drugs for Treating Depression | BARRON, SEAN C | — | §102§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSynphatec (Shanghai) Biopharmaceutical Technology Co., Ltd. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Sean C Barron has the most, with 1 of Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.'s pending office actions.